Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 1;10:614288. doi: 10.3389/fonc.2020.614288

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Saha, Kim, Amaya, Witcher, Khammanivong, Korpela, Brown, Taylor, Bryan and Dickerson

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of long-term propranolol treatment on doxorubicin cytotoxicity. COSB, DD-1, ISO-HAS, and SVR cells were treated with 50 µM propranolol every other day for two weeks, and cell viability assays were carried out 72 h after incubation with doxorubicin, doxorubicin with propranolol, or doxorubicin alone after propranolol was removed. Percent cell viability was determined by comparison to untreated control cells. The LC50 values were determined using Prism software. Data are presented as means ± S.D. of at least three independent experiments. Statistical analysis was performed by comparing the cytotoxic effect of doxorubicin (Control), doxorubicin with propranolol (Dox + Pro), or doxorubicin after the removal of propranolol (Dox – Pro) using one-way ANOVA.*p ≤ 0.05, n.s., no significance.